Contribution of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP) to the ongoing debate on the value of prostate cancer screening

BJU Int. 2022 Mar;129(3):269-270. doi: 10.1111/bju.15592.

Authors

Richard M Martin^{1

2}, Padraig Dixon³, Emma Turner¹, Edna Keeney¹

Affiliations

¹ Population Health Sciences, Bristol Medical School, University of Bristol.
² NIHR Biomedical Research Centre at University Hospitals Bristol and Weston NHS Foundation Trust, University of Bristol, Bristol, UK.
³ Nuffield Department of Primary Care Health Sciences, Medical Sciences Division, University of Oxford, Oxford, UK.

PMID: 35297158
DOI: 10.1111/bju.15592

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Early Detection of Cancer
Humans
Longitudinal Studies
Male
Mass Screening
Prostate-Specific Antigen*
Prostatic Neoplasms* / diagnosis
Prostatic Neoplasms* / prevention & control
Randomized Controlled Trials as Topic

Substances

Prostate-Specific Antigen

Grants and funding